Scientists test unusual drug duo to fight skin cancer
NCT ID NCT03620019
Summary
This study tested whether adding a bone-strengthening drug (denosumab) to a standard immunotherapy could improve the body's ability to fight advanced melanoma. It involved 25 adults with stage III or IV melanoma who had not yet received certain immunotherapies. Researchers took blood and tumor samples to see how the drug combination changed the immune system's attack on cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dartmouth-Hitchcock Medical Center
Manchester, New Hampshire, 03104, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.